CA3128204C - Isolated cell culture components and methods for isolating them from a liquid cell culture medium - Google Patents

Isolated cell culture components and methods for isolating them from a liquid cell culture medium

Info

Publication number
CA3128204C
CA3128204C CA3128204A CA3128204A CA3128204C CA 3128204 C CA3128204 C CA 3128204C CA 3128204 A CA3128204 A CA 3128204A CA 3128204 A CA3128204 A CA 3128204A CA 3128204 C CA3128204 C CA 3128204C
Authority
CA
Canada
Prior art keywords
cell culture
culture medium
biologic
liquid cell
organic solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3128204A
Other languages
English (en)
French (fr)
Other versions
CA3128204A1 (en
Inventor
Deborah Lee Bitterfield
Michael Quinn DOHERTY
Original Assignee
Lindy Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lindy Biosciences Inc filed Critical Lindy Biosciences Inc
Publication of CA3128204A1 publication Critical patent/CA3128204A1/en
Application granted granted Critical
Publication of CA3128204C publication Critical patent/CA3128204C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/10—Separation or concentration of fermentation products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/02—Separating microorganisms from their culture media
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/145—Extraction; Separation; Purification by extraction or solubilisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/06—Hydrolysis; Cell lysis; Extraction of intracellular or cell wall material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/08—Homogenizing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Sustainable Development (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CA3128204A 2019-02-05 2020-02-05 Isolated cell culture components and methods for isolating them from a liquid cell culture medium Active CA3128204C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962801225P 2019-02-05 2019-02-05
US62/801,225 2019-02-05
PCT/US2020/016743 WO2020163446A1 (en) 2019-02-05 2020-02-05 Isolated cell culture components and methods for isolating the same from liquid cell culture medium

Publications (2)

Publication Number Publication Date
CA3128204A1 CA3128204A1 (en) 2020-08-13
CA3128204C true CA3128204C (en) 2025-06-10

Family

ID=71947933

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3128204A Active CA3128204C (en) 2019-02-05 2020-02-05 Isolated cell culture components and methods for isolating them from a liquid cell culture medium

Country Status (9)

Country Link
US (2) US20220119760A1 (https=)
EP (1) EP3921082A4 (https=)
JP (2) JP2022519690A (https=)
KR (1) KR102941878B1 (https=)
CN (1) CN113661006A (https=)
AU (2) AU2020219125B2 (https=)
CA (1) CA3128204C (https=)
SG (1) SG11202107901QA (https=)
WO (1) WO2020163446A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110087763A (zh) 2016-11-22 2019-08-02 伊勒卓菲公司 包含治疗剂或诊断剂的颗粒和悬浮液以及其使用方法
AU2018306303A1 (en) 2017-07-25 2020-02-20 Elektrofi, Inc. Formation of particles including agents
WO2019226969A1 (en) 2018-05-24 2019-11-28 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
EP3917500A2 (en) 2019-01-31 2021-12-08 Elektrofi, Inc. Particle formation and morphology
CN113661006A (zh) 2019-02-05 2021-11-16 林迪生物科学公司 分离的细胞培养物组分以及用于从液体细胞培养基中分离其的方法
EP4027978A1 (en) 2019-09-13 2022-07-20 Elektrofi, Inc. Compositions and methods for the delivery of therapeutic biologics for treatment of disease
WO2021212019A1 (en) 2020-04-17 2021-10-21 Elektrofi, Inc. Methods of forming particles by continuous droplet formation and dehydration
CN112675935B (zh) * 2021-01-22 2022-03-25 中国科学院上海微系统与信息技术研究所 用于单细胞冷冻的液滴阵列芯片及液滴生成方法和应用
WO2024177927A1 (en) * 2023-02-20 2024-08-29 Lindy Biosciences, Inc. Hyaluronidase particles, compositions comprising the same and methods of making and using the same

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030143659A1 (en) * 1996-03-28 2003-07-31 Hendrik Louis Bijl Process for the preparation of a granular microbial biomass and isolation of a compound thereform
IN184589B (https=) 1996-10-16 2000-09-09 Alza Corp
US6080844A (en) * 1998-04-23 2000-06-27 Abbott Laboratories Process for the recovery and purification of a recombinant protein from a cell
GB9910975D0 (en) 1999-05-13 1999-07-14 Univ Strathclyde Rapid dehydration of proteins
JP2003033195A (ja) * 2001-07-24 2003-02-04 Kyowa Hakko Kogyo Co Ltd テトラヒドロクルクミン類の製造方法
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
CA2510196C (en) 2002-12-20 2014-04-01 Generipharm, Inc. Intracutaneous injection
US20050186183A1 (en) 2003-12-08 2005-08-25 Deangelo Joseph Stabilized products, processes and devices for preparing same
MXPA06012992A (es) 2004-05-12 2007-02-12 Baxter Int Microesferas que comprenden proteina y que muestran inyectabilidad en altas concentraciones de este agente.
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
US20060141040A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
CA2633980A1 (en) * 2005-12-29 2007-07-12 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
WO2008060786A2 (en) 2006-10-06 2008-05-22 Baxter International Inc. Microencapsules containing surface-modified microparticles and methods of forming and using the same
WO2008092084A2 (en) 2007-01-26 2008-07-31 Centocor, Inc. Injectable non-aqueous suspension with high concentration of therapeutic agent
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
GB0707938D0 (en) 2007-04-25 2007-05-30 Univ Strathclyde Precipitation stabilising compositions
US8241647B2 (en) * 2007-05-17 2012-08-14 Waseda University Amphiphilic molecule, molecular assembly comprising the amphiphilic molecule, and use of the molecular assembly
WO2009005709A1 (en) 2007-06-28 2009-01-08 Surmodics, Inc. Polypeptide microparticles
US8598378B2 (en) 2008-03-14 2013-12-03 University Of Hawaii Methods and compositions for extraction and transesterification of biomass components
US20100009007A1 (en) 2008-07-10 2010-01-14 Baxter International Inc. Non-covalent modification of microparticles and process of preparing same
SI2341905T2 (sl) 2008-09-04 2024-02-29 Amylin Pharmaceuticals, Llc Formulacije s podaljšanim sproščanjem z uporabo brezvodnih nosilcev
CN102281865B (zh) 2008-10-15 2017-04-05 精达制药公司 高浓缩药物颗粒、制剂、混悬剂及其应用
EP2376522A4 (en) 2008-11-16 2013-12-25 Univ Texas LOW VISCOSIS HIGHLY CONCENTRATED SUSPENSIONS
WO2010100564A2 (en) 2009-03-02 2010-09-10 Assistance Publique - Hopitaux De Paris Injectable biomaterial
LT2438036T (lt) * 2009-06-04 2017-06-26 Genomatica, Inc. Fermentacijos sultinio komponentų išskyrimo būdas
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US8308951B1 (en) * 2010-04-06 2012-11-13 Heliae Development, Llc Extraction of proteins by a two solvent method
BR112012025641A2 (pt) * 2010-04-06 2019-09-24 Heliae Dev Llc métodos e sistemas para produzir biocombustíveis.
WO2012012460A1 (en) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
AU2012225268B2 (en) 2011-03-10 2016-10-20 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
EA027744B1 (ru) 2011-10-31 2017-08-31 Ксерис Фармасьютикалс, Инк. Лекарственные формы для лечения сахарного диабета
WO2013067281A1 (en) 2011-11-04 2013-05-10 Battelle Memorial Institute Processes for producing protein microparticles
GB201122408D0 (en) * 2011-12-23 2012-02-08 Univ Strathclyde Method for preparing dry protein formulations
EP2849723B1 (en) 2012-05-18 2018-05-02 Genentech, Inc. High-concentration monoclonal antibody formulations
EP3006559B1 (en) * 2013-05-31 2019-11-06 iHeart Japan Corporation Layered cell sheet incorporating hydrogel
PT107846B (pt) * 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
AU2018306303A1 (en) 2017-07-25 2020-02-20 Elektrofi, Inc. Formation of particles including agents
EP3459529A1 (en) 2017-09-20 2019-03-27 Tillotts Pharma Ag Preparation of sustained release solid dosage forms comprising antibodies by spray drying
WO2019226969A1 (en) 2018-05-24 2019-11-28 Elektrofi, Inc. Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
CN113661006A (zh) 2019-02-05 2021-11-16 林迪生物科学公司 分离的细胞培养物组分以及用于从液体细胞培养基中分离其的方法
EP4027978A1 (en) * 2019-09-13 2022-07-20 Elektrofi, Inc. Compositions and methods for the delivery of therapeutic biologics for treatment of disease
WO2021212019A1 (en) 2020-04-17 2021-10-21 Elektrofi, Inc. Methods of forming particles by continuous droplet formation and dehydration

Also Published As

Publication number Publication date
CA3128204A1 (en) 2020-08-13
US20220119760A1 (en) 2022-04-21
JP2022519690A (ja) 2022-03-24
WO2020163446A1 (en) 2020-08-13
AU2020219125B2 (en) 2025-10-02
KR20210125032A (ko) 2021-10-15
KR102941878B1 (ko) 2026-03-23
EP3921082A4 (en) 2022-11-02
AU2025237973A1 (en) 2025-10-16
AU2020219125A1 (en) 2021-08-12
JP2025026925A (ja) 2025-02-26
EP3921082A1 (en) 2021-12-15
US20230093954A1 (en) 2023-03-30
US11795429B2 (en) 2023-10-24
SG11202107901QA (en) 2021-08-30
CN113661006A (zh) 2021-11-16

Similar Documents

Publication Publication Date Title
CA3128204C (en) Isolated cell culture components and methods for isolating them from a liquid cell culture medium
CN106267902B (zh) 分子的压力提高的提取和分配
JP4836786B2 (ja) 生体化合物の安定同位体標識のための組成物及び方法
CN101903512A (zh) 使用稳定的储存中间体制造生物产物的方法
Stano et al. Insights into the self-reproduction of oleate vesicles
CN119534244A (zh) 用于确定包含核酸如rna和任选存在的颗粒的样品组合物的至少一个参数的方法
JP2020507593A (ja) タンパク質処理用賦形剤化合物
Ferreira-Faria et al. Continuous precipitation of antibodies using oscillatory flow reactor: a proof of concept
Kumar et al. Fundamentals and applications of lyophilization
Thömmes et al. Alternatives to Packed‐Bed Chromatography for Antibody Extraction and Purification
Fahim et al. Boosting protein crystallization from liquid-liquid phase separation by increasing metastability gap
FI127353B (en) Concentration and purification of hydrophobins and antibodies by phase separation
KR20260053026A (ko) 단리된 세포 배양 성분 및 액체 세포 배양 배지로부터 이를 단리하는 방법
Sinha et al. Advances in downstream processing techniques
Sadana Bioseparations of proteins: unfolding/folding and validations
Hong et al. Nanosuspended branched chain amino acids: the influence of stabilizers on their solubility and colloidal stability
Sarup Investigation of supercritical fluid technology to produce dry particulate formulations of antibody fragments
Lehmkuhl et al. Separation and purification of CHO secretome and extracellular vesicles for proteome analysis
König et al. Development of a pilot-scale manufacturing process for protein-coated microcrystals (PCMC): Mixing and precipitation–Part I
Franks In Vitro Characterization: Economics and Technology
Nayem Studying solution self-assembled morphology and thermal stability of Polysorbate fractions and their implications in micellar degradation via small angle neutron scattering
Schlegl et al. Purification and formulation: Silent but important players in vaccine development
Ward et al. Refractive index matching to develop transparent polyaphrons: Characterization of immobilized proteins
Fazeli et al. Optimization of fed-batch refolding in downstream process of recombinant interferon β1b
Llompart Zera® technology: a versatile platform for protein manufacturing

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220923

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20240717

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241216

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241216

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241216

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20250509

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250509

Q17 Modified document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q17-Q103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DOCUMENT PUBLISHED

Effective date: 20250604

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-4-4-F10-F11-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: GRANT BY ISSUANCE

Effective date: 20250610

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251216

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251216